The Therapeutic Potential and Molecular Mechanisms Underlying the Neuroprotective Effects of Sativex^® - A Cannabis-derived Spray

Russo, E.B. History of cannabis and its preparations in saga, science, and sobriquet. Chem. Biodivers., 2007, 4(8), 1614-1648.
[http://dx.doi.org/10.1002/cbdv.200790144] [PMID: 17712811]

Russo, E.B. Synthetic and natural cannabinoids: The cardiovascular risk. Br. J. Cardiol., 2015, 22, 7-9.

Pertwee, R.G. Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br. J. Pharmacol., 2009, 156(3), 397-411.
[http://dx.doi.org/10.1111/j.1476-5381.2008.00048.x] [PMID: 19226257]

Russo, E.; Guy, G.W. A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol. Med. Hypotheses, 2006, 66(2), 234-246.
[http://dx.doi.org/10.1016/j.mehy.2005.08.026] [PMID: 16209908]

Hernández-Tiedra, S.; Fabriàs, G.; Dávila, D.; Salanueva, Í.J.; Casas, J.; Montes, L.R.; Antón, Z.; García-Taboada, E.; Salazar-Roa, M.; Lorente, M.; Nylandsted, J.; Armstrong, J.; López-Valero, I.; McKee, C.S.; Serrano-Puebla, A.; García-López, R.; González- Martínez, J.; Abad, J.L.; Hanada, K.; Boya, P.; Goñi, F.; Guzmán, M.; Lovat, P.; Jäättelä, M.; Alonso, A.; Velasco, G. Dihydroceramide accumulation mediates cytotoxic autophagy of cancer cells via autolysosome destabilization. Autophagy, 2016, 12(11), 2213-2229.
[http://dx.doi.org/10.1080/15548627.2016.1213927] [PMID: 27635674]

Spray, S.O. Summary of product characteristics; GW Pharma Ltd., 2020.

D’hooghe, M.; Willekens, B.; Delvaux, V.; D’haeseleer, M.; Guillaume, D.; Laureys, G.; Nagels, G.; Vanderdonckt, P.; Van Pesch, V.; Popescu, V. Sativex® (nabiximols) cannabinoid oromucosal spray in patients with resistant multiple sclerosis spasticity: The Belgian experience. BMC Neurol., 2021, 21(1), 227.
[http://dx.doi.org/10.1186/s12883-021-02246-0] [PMID: 34157999]

Messina, S.; Solaro, C.; Righini, I.; Bergamaschi, R.; Bonavita, S.; Bossio, R.B.; Brescia Morra, V.; Costantino, G.; Cavalla, P.; Centonze, D.; Comi, G.; Cottone, S.; Danni, M.C.; Francia, A.; Gajofatto, A.; Gasperini, C.; Zaffaroni, M.; Petrucci, L.; Signoriello, E.; Maniscalco, G.T.; Spinicci, G.; Matta, M.; Mirabella, M.; Pedà, G.; Castelli, L.; Rovaris, M.; Sessa, E.; Spitaleri, D.; Paolicelli, D.; Granata, A.; Zappia, M.; Patti, F. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). PLoS One, 2017, 12(8), e0180651.
[http://dx.doi.org/10.1371/journal.pone.0180651] [PMID: 28763462]

Console-Bram, L.; Marcu, J.; Abood, M.E. Cannabinoid receptors: nomenclature and pharmacological principles. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2012, 38(1), 4-15.
[http://dx.doi.org/10.1016/j.pnpbp.2012.02.009] [PMID: 22421596]

Cabral, G.A.; Raborn, E.S.; Griffin, L.; Dennis, J.; Marciano-Cabral, F. CB 2 receptors in the brain: Role in central immune function. Br. J. Pharmacol., 2008, 153(2), 240-251.
[http://dx.doi.org/10.1038/sj.bjp.0707584] [PMID: 18037916]

Fernández-Ruiz, J.; Hernández, M.; Ramos, J.A. Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders. CNS Neurosci. Ther., 2010, 16(3), e72-e91.
[http://dx.doi.org/10.1111/j.1755-5949.2010.00144.x] [PMID: 20406253]

Boczek, T.; Zylinska, L. Receptor-dependent and independent regulation of voltage-gated Ca2+ channels and Ca2+-permeable channels by endocannabinoids in the brain. Int. J. Mol. Sci., 2021, 22(15), 8168.
[http://dx.doi.org/10.3390/ijms22158168] [PMID: 34360934]

Lin, Y.F. Potassium channels as molecular targets of endocannabinoids. Channels, 2021, 15(1), 408-423.
[http://dx.doi.org/10.1080/19336950.2021.1910461] [PMID: 34282702]

Haghani, M.; Shabani, M.; Javan, M.; Motamedi, F.; Janahmadi, M. CB1 cannabinoid receptor activation rescues amyloid β-induced alterations in behaviour and intrinsic electrophysiological properties of rat hippocampal CA1 pyramidal neurones. Cell. Physiol. Biochem., 2012, 29(3-4), 391-406.
[http://dx.doi.org/10.1159/000338494] [PMID: 22508047]

Sancho, M.; Fletcher, J.; Welsh, D.G. Inward rectifier potassium channels: Membrane lipid-dependent mechanosensitive gates in brain vascular cells. Front. Cardiovasc. Med., 2022, 9, 869481.
[http://dx.doi.org/10.3389/fcvm.2022.869481] [PMID: 35419431]

Li, Y.; Aziz, Q.; Tinker, A. The pharmacology of ATP-sensitive K+ channels (KATP). Handb. Exp. Pharmacol., 2021, 267, 357-378.

Hager, N.A.; McAtee, C.K.; Lesko, M.A.; O’Donnell, A.F. Inwardly rectifying potassium channel kir2.1 and its “kir-ious” regulation by protein trafficking and roles in development and disease. Front. Cell Dev. Biol., 2022, 9, 796136.
[http://dx.doi.org/10.3389/fcell.2021.796136] [PMID: 35223865]

De Petrocellis, L.; Vellani, V.; Schiano-Moriello, A.; Marini, P.; Magherini, P.C.; Orlando, P.; Di Marzo, V. Plant-derived cannabinoids modulate the activity of transient receptor potential channels of ankyrin type-1 and melastatin type-8. J. Pharmacol. Exp. Ther., 2008, 325(3), 1007-1015.
[http://dx.doi.org/10.1124/jpet.107.134809] [PMID: 18354058]

Petrosino, S.; Di Marzo, V. FAAH and MAGL inhibitors: Therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs, 2010, 11(1), 51-62.
[PMID: 20047159]

Blankman, J.L.; Gabriel, M.S.; Benjamin, F.S. A comprehensive profile of brain enzymes that hydrolyze the endocannabinoid 2-arachidonoylglycerol. Chem. Biol., 2007, 14(12), 1347-1356.

Basu, S.; Dittel, B.N. Unraveling the complexities of cannabinoid receptor 2 (CB2) immune regulation in health and disease. Immunol. Res., 2011, 51(1), 26-38.
[http://dx.doi.org/10.1007/s12026-011-8210-5] [PMID: 21626285]

Rieder, S.A.; Chauhan, A.; Singh, U.; Nagarkatti, M.; Nagarkatti, P. Cannabinoid-induced apoptosis in immune cells as a pathway to immunosuppression. Immunobiology, 2010, 215(8), 598-605.
[http://dx.doi.org/10.1016/j.imbio.2009.04.001] [PMID: 19457575]

Karschner, E.L.; Darwin, W.D.; McMahon, R.P.; Liu, F.; Wright, S.; Goodwin, R.S.; Huestis, M.A. Subjective and physiological effects after controlled Sativex and oral THC administration. Clin. Pharmacol. Ther., 2011, 89(3), 400-407.
[http://dx.doi.org/10.1038/clpt.2010.318] [PMID: 21289620]

Molnar, A.; Fu, S. Techniques and technologies for the bioanalysis of Sativex ®, metabolites and related compounds. Bioanalysis, 2016, 8(8), 829-845.
[http://dx.doi.org/10.4155/bio-2015-0021] [PMID: 27005853]

Novotna, A.; Mares, J.; Ratcliffe, S.; Novakova, I.; Vachova, M.; Zapletalova, O.; Gasperini, C.; Pozzilli, C.; Cefaro, L.; Comi, G.; Rossi, P.; Ambler, Z.; Stelmasiak, Z.; Erdmann, A.; Montalban, X.; Klimek, A.; Davies, P. A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex ®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis. Eur. J. Neurol., 2011, 18(9), 1122-1131.
[http://dx.doi.org/10.1111/j.1468-1331.2010.03328.x] [PMID: 21362108]

Karst, M.; Wippermann, S.; Ahrens, J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs, 2010, 70(18), 2409-2438.
[http://dx.doi.org/10.2165/11585260-000000000-00000] [PMID: 21142261]

Rahn, E.J.; Hohmann, A.G. Cannabinoids as pharmacotherapies for neuropathic pain: From the bench to the bedside. Neurotherapeutics, 2009, 6(4), 713-737.
[http://dx.doi.org/10.1016/j.nurt.2009.08.002] [PMID: 19789075]

Treede, R.D.; Jensen, T.S.; Campbell, J.N.; Cruccu, G.; Dostrovsky, J.O.; Griffin, J.W.; Hansson, P.; Hughes, R.; Nurmikko, T.; Serra, J. Neuropathic pain. Neurology, 2008, 70(18), 1630-1635.
[http://dx.doi.org/10.1212/01.wnl.0000282763.29778.59] [PMID: 18003941]

Jensen, T.S.; Baron, R. Haanpää, M.; Kalso, E.; Loeser, J.D.; Rice, A.S.C.; Treede, R.D. A new definition of neuropathic pain. Pain, 2011, 152(10), 2204-2205.
[http://dx.doi.org/10.1016/j.pain.2011.06.017] [PMID: 21764514]

Vadivelu, N.; Kai, A.M.; Kodumudi, V.; Sramcik, J.; Kaye, A.D. The opioid crisis: A comprehensive overview. Curr. Pain Headache Rep., 2018, 22(3), 16.
[http://dx.doi.org/10.1007/s11916-018-0670-z] [PMID: 29476358]

Yang, J.; Bauer, B.A.; Wahner-Roedler, D.L.; Chon, T.Y.; Xiao, L. The modified WHO analgesic ladder: Is it appropriate for chronic non-cancer pain? J. Pain Res., 2020, 13, 411-417.
[http://dx.doi.org/10.2147/JPR.S244173] [PMID: 32110089]

Johnson, J.R.; Burnell-Nugent, M.; Lossignol, D.; Ganae-Motan, E.D.; Potts, R.; Fallon, M.T. Multicenter, double-blind, randomized, placebo-controlled, parallel-group study of the efficacy, safety, and tolerability of THC:CBD extract and THC extract in patients with intractable cancer-related pain. J. Pain Symptom Manage., 2010, 39(2), 167-179.
[http://dx.doi.org/10.1016/j.jpainsymman.2009.06.008] [PMID: 19896326]

Aviram, J.; Samuelly-Leichtag, G. Efficacy of cannabis-based medicines for pain management: A systematic review and metaanalysis of randomized controlled trials. Pain Physician, 2017, 6(20;6), E755-E796.
[http://dx.doi.org/10.36076/ppj.20.5.E755] [PMID: 28934780]

Mücke, M.; Phillips, T.; Radbruch, L.; Petzke, F. Häuser, W. Cannabis-based medicines for chronic neuropathic pain in adults. Cochrane Database Syst. Rev., 2018, 3(3), CD012182.
[PMID: 29513392]

van de Donk, T.; Niesters, M.; Kowal, M.A.; Olofsen, E.; Dahan, A.; van Velzen, M. An experimental randomized study on the analgesic effects of pharmaceutical-grade cannabis in chronic pain patients with fibromyalgia. Pain, 2019, 160(4), 860-869.
[http://dx.doi.org/10.1097/j.pain.0000000000001464] [PMID: 30585986]

VanDolah, H.J.; Bauer, B.A.; Mauck, K.F. Clinicians’ Guide to cannabidiol and hemp oils. Mayo Clin. Proc., 2019, 94(9), 1840-1851.
[http://dx.doi.org/10.1016/j.mayocp.2019.01.003] [PMID: 31447137]

Capano, A.; Weaver, R.; Burkman, E. Evaluation of the effects of CBD hemp extract on opioid use and quality of life indicators in chronic pain patients: A prospective cohort study. Postgrad. Med., 2020, 132(1), 56-61.
[http://dx.doi.org/10.1080/00325481.2019.1685298] [PMID: 31711352]

Medicines, C-B.J.D.R.D. Cannabis-based medicines--GW pharmaceuticals: High CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD. Drugs R D., 2003, 4(5), 306-309.
[PMID: 12952500]

Häuser, W.; Finn, D.P.; Kalso, E.; Krcevski-Skvarc, N.; Kress, H.G.; Morlion, B.; Perrot, S.; Schäfer, M.; Wells, C.; Brill, S. European pain federation (EFIC) position paper on appropriate use of cannabis-based medicines and medical cannabis for chronic pain management. Eur. J. Pain, 2018, 22(9), 1547-1564.
[http://dx.doi.org/10.1002/ejp.1297] [PMID: 30074291]

Prieto González, J.M.; Vila Silván, C. Safety and tolerability of nabiximols oromucosal spray: A review of more than 15 years” accumulated evidence from clinical trials. Expert Rev. Neurother., 2021, 21(7), 755-778.
[http://dx.doi.org/10.1080/14737175.2021.1935879] [PMID: 34092180]

Barnes, M.P. Sativex ®: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain. Expert Opin. Pharmacother., 2006, 7(5), 607-615.
[http://dx.doi.org/10.1517/14656566.7.5.607] [PMID: 16553576]

Turner, M.R.; Cagnin, A.; Turkheimer, F.E.; Miller, C.C.J.; Shaw, C.E.; Brooks, D.J.; Leigh, P.N.; Banati, R.B. Evidence of widespread cerebral microglial activation in amyotrophic lateral sclerosis: an [11C](R)-PK11195 positron emission tomography study. Neurobiol. Dis., 2004, 15(3), 601-609.
[http://dx.doi.org/10.1016/j.nbd.2003.12.012] [PMID: 15056468]

Berman, J.S.; Symonds, C.; Birch, R. Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: Results of a randomised controlled trial. Pain, 2004, 112(3), 299-306.
[http://dx.doi.org/10.1016/j.pain.2004.09.013] [PMID: 15561385]

Turri, M.; Teatini, F.; Donato, F.; Zanette, G.; Tugnoli, V.; Deotto, L.; Bonetti, B.; Squintani, G. Pain modulation after oromucosal cannabinoid spray (SATIVEX®) in patients with multiple sclerosis: A study with quantitative sensory testing and laser-evoked potentials. Medicines, 2018, 5(3), 59.
[http://dx.doi.org/10.3390/medicines5030059] [PMID: 29933552]

Langford, R.M.; Mares, J.; Novotna, A.; Vachova, M.; Novakova, I.; Notcutt, W.; Ratcliffe, S. A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J. Neurol., 2013, 260(4), 984-997.
[http://dx.doi.org/10.1007/s00415-012-6739-4] [PMID: 23180178]

Watkins, A.R. Cannabinoid interactions with ion channels and receptors. Channels, 2019, 13(1), 162-167.
[http://dx.doi.org/10.1080/19336950.2019.1615824] [PMID: 31088312]

Ghovanloo, M.R.; Shuart, N.G.; Mezeyova, J.; Dean, R.A.; Ruben, P.C.; Goodchild, S.J. Inhibitory effects of cannabidiol on voltage-dependent sodium currents. J. Biol. Chem., 2018, 293(43), 16546-16558.
[http://dx.doi.org/10.1074/jbc.RA118.004929] [PMID: 30219789]

Bisogno, T. Hanuš, L.; De Petrocellis, L.; Tchilibon, S.; Ponde, D.E.; Brandi, I.; Moriello, A.S.; Davis, J.B.; Mechoulam, R.; Di Marzo, V. Molecular targets for cannabidiol and its synthetic analogues: Effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol., 2001, 134(4), 845-852.
[http://dx.doi.org/10.1038/sj.bjp.0704327] [PMID: 11606325]

Gülck, T. Møller, B.L. Phytocannabinoids: Origins and biosynthesis. Trends Plant Sci., 2020, 25(10), 985-1004.
[http://dx.doi.org/10.1016/j.tplants.2020.05.005] [PMID: 32646718]

Yang, Y.; Vyawahare, R.; Lewis-Bakker, M.; Clarke, H.A.; Wong, A.H.C.; Kotra, L.P. Bioactive chemical composition of cannabis extracts and cannabinoid receptors. Molecules, 2020, 25(15), 3466.
[http://dx.doi.org/10.3390/molecules25153466] [PMID: 32751516]

Millar, S.A.; Stone, N.L.; Yates, A.S.; O’Sullivan, S.E. A systematic review on the pharmacokinetics of cannabidiol in humans. Front. Pharmacol., 2018, 9, 1365.
[http://dx.doi.org/10.3389/fphar.2018.01365] [PMID: 30534073]

Gruber, S.A.; Sagar, K.A. Marijuana on the mind? The impact of marijuana on cognition, brain structure, and brain function, and related public policy implications. Policy Insights Behav. Brain Sci., 2017, 4(1), 104-111.
[http://dx.doi.org/10.1177/2372732216684851]

Becker, B.; Wagner, D.; Gouzoulis-Mayfrank, E.; Spuentrup, E.; Daumann, J. The impact of early-onset cannabis use on functional brain correlates of working memory. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2010, 34(6), 837-845.
[http://dx.doi.org/10.1016/j.pnpbp.2010.03.032] [PMID: 20363277]

Theiler, M. Spontaneous encephalomyelitis of mice, a new virus disease. J. Exp. Med., 1937, 65(5), 705-719.
[http://dx.doi.org/10.1084/jem.65.5.705] [PMID: 19870629]

Denic, A.; Johnson, A.J.; Bieber, A.J.; Warrington, A.E.; Rodriguez, M.; Pirko, I. The relevance of animal models in multiple sclerosis research. Pathophysiology, 2011, 18(1), 21-29.
[http://dx.doi.org/10.1016/j.pathophys.2010.04.004] [PMID: 20537877]

Pirko, I.; Gamez, J.; Johnson, A.J.; Macura, S.I.; Rodriguez, M. Dynamics of MRI lesion development in an animal model of viral-induced acute progressive CNS demyelination. Neuroimage, 2004, 21(2), 576-582.
[http://dx.doi.org/10.1016/j.neuroimage.2003.09.037] [PMID: 14980559]

Pirko, I.; Suidan, G.L.; Rodriguez, M.; Johnson, A.J. Acute hemorrhagic demyelination in a murine model of multiple sclerosis. J. Neuroinflam., 2008, 5(1), 31.
[http://dx.doi.org/10.1186/1742-2094-5-31] [PMID: 18606015]

Kipp, M.; Clarner, T.; Dang, J.; Copray, S.; Beyer, C. The cuprizone animal model: New insights into an old story. Acta Neuropathol., 2009, 118(6), 723-736.
[http://dx.doi.org/10.1007/s00401-009-0591-3] [PMID: 19763593]

Zhan, J.; Mann, T.; Joost, S.; Behrangi, N.; Frank, M.; Kipp, M. The cuprizone model: Dos and do nots. Cells, 2020, 9(4), 843.
[http://dx.doi.org/10.3390/cells9040843] [PMID: 32244377]

Rivers, T.M.; Sprunt, D.H.; Berry, G.P. Observations on attempts to produce acute disseminated encephalomyelitis in monkeyS. J. Exp. Med., 1933, 58(1), 39-53.
[http://dx.doi.org/10.1084/jem.58.1.39] [PMID: 19870180]

Gerhauser, I.; Hansmann, F.; Ciurkiewicz, M. Löscher, W.; Beineke, A. Facets of theiler’s murine encephalomyelitis virus-induced diseases: An update. Int. J. Mol. Sci., 2019, 20(2), 448.
[http://dx.doi.org/10.3390/ijms20020448] [PMID: 30669615]

Wolf, A.; Kabat, E.A.; Bezer, A. The pathology of acute disseminated encephalomyelitis produced experimentally in the rhesus monkey and its resemblance to human demyelinating disease. J. Neuropathol. Exp. Neurol., 1947, 6(4), 333-357.
[http://dx.doi.org/10.1097/00005072-194710000-00003] [PMID: 20267714]

Bruni, N.; Della Pepa, C.; Oliaro-Bosso, S.; Pessione, E.; Gastaldi, D.; Dosio, F. Cannabinoid delivery systems for pain and inflammation treatment. Molecules, 2018, 23(10), 2478.
[http://dx.doi.org/10.3390/molecules23102478] [PMID: 30262735]

Vlachou, S.; Nomikos, G.G.; Stephens, D.N.; Panagis, G. Lack of evidence for appetitive effects of Δ9-tetrahydrocannabinol in the intracranial self-stimulation and conditioned place preference procedures in rodents. Behav. Pharmacol., 2007, 18(4), 311-319.
[http://dx.doi.org/10.1097/FBP.0b013e3282186cf2] [PMID: 17551324]

Losseff, N.A.; Webb, S.L.; O’Riordan, J.I.; Page, R.; Wang, L.; Barker, G.J.; Tofts, P.S.; McDonald, W.I.; Miller, D.H.; Thompson, A.J. Spinal cord atrophy and disability in multiple sclerosis. Brain, 1996, 119(3), 701-708.
[http://dx.doi.org/10.1093/brain/119.3.701] [PMID: 8673483]

Lassmann, H. Neuropathology in multiple sclerosis: New concepts. Mult. Scler., 1998, 4(3), 93-98.
[http://dx.doi.org/10.1177/135245859800400301] [PMID: 9762654]

Rudick, R.A. Disease-modifying drugs for relapsing-remitting multiple sclerosis and future directions for multiple sclerosis therapeutics. Arch. Neurol., 1999, 56(9), 1079-1084.
[http://dx.doi.org/10.1001/archneur.56.9.1079] [PMID: 10488808]

Milo, R.; Miller, A. Revised diagnostic criteria of multiple sclerosis. Autoimmun. Rev., 2014, 13(4-5), 518-524.
[http://dx.doi.org/10.1016/j.autrev.2014.01.012] [PMID: 24424194]

Eisenreich, W.; Schwarz, M.; Cartayrade, A.; Arigoni, D.; Zenk, M.H.; Bacher, A. The deoxyxylulose phosphate pathway of terpenoid biosynthesis in plants and microorganisms. Chem. Biol., 1998, 5(9), R221-R233.
[http://dx.doi.org/10.1016/S1074-5521(98)90002-3] [PMID: 9751645]

Appendino, G.; Chianese, G.; Taglialatela-Scafati, O. Cannabinoids: Occurrence and medicinal chemistry. Curr. Med. Chem., 2011, 18(7), 1085-1099.
[http://dx.doi.org/10.2174/092986711794940888] [PMID: 21254969]

Jones, É.; Vlachou, S. A critical review of the role of the cannabinoid compounds δ9-tetrahydrocannabinol (Δ9-THC) and cannabidiol (CBD) and their combination in multiple sclerosis treatment. Molecules, 2020, 25(21), 4930.
[http://dx.doi.org/10.3390/molecules25214930] [PMID: 33113776]

Hilliard, A.; Stott, C.; Wright, S.; Guy, G.; Pryce, G.; Al-Izki, S.; Bolton, C.; Giovannoni, G. Evaluation of the effects of sativex (THC BDS: CBD BDS) on inhibition of spasticity in a chronic relapsing experimental allergic autoimmune encephalomyelitis: A model of multiple sclerosis. ISRN Neurol., 2012, 2012, 1-7.
[http://dx.doi.org/10.5402/2012/802649] [PMID: 22928118]

Dybowski, M.P.; Dawidowicz, A.L.; Typek, R.; Rombel, M. Conversion of cannabidiol (CBD) to Δ9-tetrahydrocannabinol (Δ9-THC) during protein precipitations prior to plasma samples analysis by chromatography – Troubles with reliable CBD quantitation when acidic precipitation agents are applied. Talanta, 2020, 220, 121390.
[http://dx.doi.org/10.1016/j.talanta.2020.121390] [PMID: 32928411]

Banister, S.D.; Arnold, J.C.; Connor, M.; Glass, M.; McGregor, I.S. Dark classics in chemical neuroscience: Δ9 -Tetrahydrocannabinol. ACS Chem. Neurosci., 2019, 10(5), 2160-2175.
[http://dx.doi.org/10.1021/acschemneuro.8b00651] [PMID: 30689342]

Moreno-Martet, M. Feliú, A.; Espejo-Porras, F.; Mecha, M.; Carrillo-Salinas, F.J.; Fernández-Ruiz, J.; Guaza, C.; de Lago, E. The disease-modifying effects of a Sativex-like combination of phytocannabinoids in mice with experimental autoimmune encephalomyelitis are preferentially due to Δ-tetrahydrocannabinol acting through CB1 receptors. Mult. Scler. Relat. Disord., 2015, 4(6), 505-511.
[http://dx.doi.org/10.1016/j.msard.2015.08.001] [PMID: 26590655]

Al-Ghezi, Z.Z.; Busbee, P.B.; Alghetaa, H.; Nagarkatti, P.S.; Nagarkatti, M. Combination of cannabinoids, delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), mitigates experimental autoimmune encephalomyelitis (EAE) by altering the gut microbiome. Brain Behav. Immun., 2019, 82, 25-35.
[http://dx.doi.org/10.1016/j.bbi.2019.07.028] [PMID: 31356922]

Sriram, S.; Steiner, I. Experimental allergic encephalomyelitis: A misleading model of multiple sclerosis. Ann. Neurol., 2005, 58(6), 939-945.
[http://dx.doi.org/10.1002/ana.20743] [PMID: 16315280]

Rog, D.J.; Nurmikko, T.J.; Friede, T.; Young, C.A. Randomized, controlled trial of cannabis-based medicine in central pain in multiple sclerosis. Neurology, 2005, 65(6), 812-819.
[http://dx.doi.org/10.1212/01.wnl.0000176753.45410.8b] [PMID: 16186518]

Schimrigk, S.; Marziniak, M.; Neubauer, C.; Kugler, E.M.; Werner, G.; Abramov-Sommariva, D. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur. Neurol., 2017, 78(5-6), 320-329.
[http://dx.doi.org/10.1159/000481089] [PMID: 29073592]

Goncharov, N. Nutraceuticals: Efficacy, Safety and Toxicity; Gupta, R.C., Ed.; Academic Press, 2016, p. 177.
[http://dx.doi.org/10.1016/B978-0-12-802147-7.00014-0]

Elliott, D.M.; Singh, N.; Nagarkatti, M.; Nagarkatti, P.S. Cannabidiol attenuates experimental autoimmune encephalomyelitis model of multiple sclerosis through induction of myeloid-derived suppressor cells. Front. Immunol., 2018, 9, 1782.
[http://dx.doi.org/10.3389/fimmu.2018.01782] [PMID: 30123217]

González-García, C.; Irene, M.T.; García-Hernández, R. Mechanisms of action of cannabidiol in adoptively transferred experimental autoimmune encephalomyelitis. Exp Neurol, 2017, 298(Pt A), 57-67.
[http://dx.doi.org/10.1016/j.expneurol.2017.08.017]

Al-Ghezi, Z.Z.; Miranda, K.; Nagarkatti, M.; Nagarkatti, P.S. Combination of cannabinoids, δ9- tetrahydrocannabinol and cannabidiol, ameliorates experimental multiple sclerosis by suppressing neuroinflammation through regulation of miRNA-mediated signaling pathways. Front. Immunol., 2019, 10, 1921.
[http://dx.doi.org/10.3389/fimmu.2019.01921] [PMID: 31497013]

Ujváry, I.; Hanuš, L. Human metabolites of cannabidiol: A review on their formation, biological activity, and relevance in therapy. Cannabis Cannabinoid Res., 2016, 1(1), 90-101.
[http://dx.doi.org/10.1089/can.2015.0012] [PMID: 28861484]

Marková, J. Newest evidence for tetrahydrocannabinol: Cannabidiol oromucosal spray from randomized clinical trials. Neurodegener. Dis. Manag., 2019, 9(2s), 9-13.
[http://dx.doi.org/10.2217/nmt-2018-0050] [PMID: 30657024]

Markovà, J.; Essner, U.; Akmaz, B.; Marinelli, M.; Trompke, C.; Lentschat, A.; Vila, C. Sativex ® as add-on therapy vs. further optimized first-line ANTispastics (SAVANT) in resistant multiple sclerosis spasticity: A double-blind, placebo-controlled randomised clinical trial. Int. J. Neurosci., 2019, 129(2), 119-128.
[http://dx.doi.org/10.1080/00207454.2018.1481066] [PMID: 29792372]

Marinelli, L.; Mori, L.; Canneva, S.; Colombano, F.; Currà, A.; Fattapposta, F.; Bandini, F.; Capello, E.; Abbruzzese, G.; Trompetto, C. The effect of cannabinoids on the stretch reflex in multiple sclerosis spasticity. Int. Clin. Psychopharmacol., 2016, 31(4), 232-239.
[http://dx.doi.org/10.1097/YIC.0000000000000126] [PMID: 27003093]

Ferrè, L.; Nuara, A.; Pavan, G.; Radaelli, M.; Moiola, L.; Rodegher, M.; Colombo, B.; Keller Sarmiento, I.J.; Martinelli, V.; Leocani, L.; Martinelli, B.F.; Comi, G.; Esposito, F. Efficacy and safety of nabiximols (Sativex®) on multiple sclerosis spasticity in a real-life Italian monocentric study. Neurol. Sci., 2016, 37(2), 235-242.
[http://dx.doi.org/10.1007/s10072-015-2392-x] [PMID: 26474875]

Leocani, L.; Nuara, A.; Houdayer, E.; Schiavetti, I.; Del Carro, U.; Amadio, S.; Straffi, L.; Rossi, P.; Martinelli, V.; Vila, C.; Sormani, M.P.; Comi, G. Sativex® and clinical–neurophysiological measures of spasticity in progressive multiple sclerosis. J. Neurol., 2015, 262(11), 2520-2527.
[http://dx.doi.org/10.1007/s00415-015-7878-1] [PMID: 26289497]

Savinainen, J.R.; Saario, S.M.; Niemi, R. Järvinen, T.; Laitinen, J.T. An optimized approach to study endocannabinoid signaling: evidence against constitutive activity of rat brain adenosine A 1 and cannabinoid CB 1 receptors. Br. J. Pharmacol., 2003, 140(8), 1451-1459.
[http://dx.doi.org/10.1038/sj.bjp.0705577] [PMID: 14623770]

Russo, M.; Naro, A.; Leo, A.; Sessa, E.; D’Aleo, G.; Bramanti, P. Calabrò, R.S. Evaluating sativex ® in neuropathic pain management: A clinical and neurophysiological assessment in multiple sclerosis. Pain Med., 2016, 17(6), pnv080.
[http://dx.doi.org/10.1093/pm/pnv080] [PMID: 26764336]

Schneider, L.S.; Clark, C.M.; Doody, R.; Ferris, S.H.; Morris, J.C.; Raman, R.; Reisberg, B.; Schmitt, F.A. ADCS prevention instrument project: Adcs-clinicians’ global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. Alzheimer Dis. Assoc. Disord., 2006, 20(4), S124-S138.
[http://dx.doi.org/10.1097/01.wad.0000213878.47924.44] [PMID: 17135806]

Im, D.D.; Jambaulikar, G.D.; Kikut, A.; Gale, J.; Weiner, S.G. Brief pain inventory–short form: A new method for assessing pain in the emergency department. Pain Med., 2020, 21(12), 3263-3269.
[http://dx.doi.org/10.1093/pm/pnaa269] [PMID: 32918473]

Caprariello, A.V.; Rogers, J.A.; Morgan, M.L.; Hoghooghi, V.; Plemel, J.R.; Koebel, A.; Tsutsui, S.; Dunn, J.F.; Kotra, L.P.; Ousman, S.S.; Wee Yong, V.; Stys, P.K. Biochemically altered myelin triggers autoimmune demyelination. Proc. Natl. Acad. Sci., 2018, 115(21), 5528-5533.
[http://dx.doi.org/10.1073/pnas.1721115115] [PMID: 29728463]

Manterola, A.; Bernal-Chico, A.; Cipriani, R.; Canedo-Antelo, M. Moreno-García, Á.; Martín-Fontecha, M.; Pérez-Cerdá, F.; Sánchez-Gómez, M.V.; Ortega-Gutiérrez, S.; Brown, J.M.; Hsu, K.L.; Cravatt, B.; Matute, C.; Mato, S. Deregulation of the endocannabinoid system and therapeutic potential of ABHD6 blockade in the cuprizone model of demyelination. Biochem. Pharmacol., 2018, 157, 189-201.
[http://dx.doi.org/10.1016/j.bcp.2018.07.042] [PMID: 30075103]

Allsop, D.J.; Copeland, J.; Lintzeris, N.; Dunlop, A.J.; Montebello, M.; Sadler, C.; Rivas, G.R.; Holland, R.M.; Muhleisen, P.; Norberg, M.M.; Booth, J.; McGregor, I.S. Nabiximols as an agonist replacement therapy during cannabis withdrawal: A randomized clinical trial. JAMA Psychiatry, 2014, 71(3), 281-291.
[http://dx.doi.org/10.1001/jamapsychiatry.2013.3947] [PMID: 24430917]

Nicholson, A.N.; Turner, C.; Stone, B.M.; Robson, P.J. Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults. J. Clin. Psychopharmacol., 2004, 24(3), 305-313.
[http://dx.doi.org/10.1097/01.jcp.0000125688.05091.8f] [PMID: 15118485]

Hardiman, O.; van den Berg, L.H.; Kiernan, M.C. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat. Rev. Neurol., 2011, 7(11), 639-649.
[http://dx.doi.org/10.1038/nrneurol.2011.153] [PMID: 21989247]

Renton, A.E. Chiò, A.; Traynor, B.J. State of play in amyotrophic lateral sclerosis genetics. Nat. Neurosci., 2014, 17(1), 17-23.
[http://dx.doi.org/10.1038/nn.3584] [PMID: 24369373]

Ferraiuolo, L.; Kirby, J.; Grierson, A.J.; Sendtner, M.; Shaw, P.J. Molecular pathways of motor neuron injury in amyotrophic lateral sclerosis. Nat. Rev. Neurol., 2011, 7(11), 616-630.
[http://dx.doi.org/10.1038/nrneurol.2011.152] [PMID: 22051914]

Foran, E.; Trotti, D. Glutamate transporters and the excitotoxic path to motor neuron degeneration in amyotrophic lateral sclerosis. Antioxid. Redox Signal., 2009, 11(7), 1587-1602.
[http://dx.doi.org/10.1089/ars.2009.2444] [PMID: 19413484]

Habib, A.A.; Mitsumoto, H. Emerging drugs for amyotrophic lateral sclerosis. Expert Opin. Emerg. Drugs, 2011, 16(3), 537-558.
[http://dx.doi.org/10.1517/14728214.2011.604312] [PMID: 21806316]

Bilsland, L.; Greensmith, L. The endocannabinoid system in amyotrophic lateral sclerosis. Curr. Pharm. Des., 2008, 14(23), 2306-2316.
[http://dx.doi.org/10.2174/138161208785740081] [PMID: 18781981]

Raman, C.; McAllister, S.D.; Rizvi, G.; Patel, S.G.; Moore, D.H.; Abood, M.E. Amyotrophic lateral sclerosis: Delayed disease progression in mice by treatment with a cannabinoid. Amyotroph. Lateral Scler. Other Motor Neuron Disord., 2004, 5(1), 33-39.
[http://dx.doi.org/10.1080/14660820310016813] [PMID: 15204022]

Weydt, P.; Hong, S.; Witting, A. Möller, T.; Stella, N.; Kliot, M. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotroph. Lateral Scler., 2005, 6(3), 182-184.
[http://dx.doi.org/10.1080/14660820510030149] [PMID: 16183560]

Bilsland, L.G.; Dick, J.R.T.; Pryce, G.; Petrosino, S.; Di Marzo, V.; Baker, D.; Greensmith, L.; Bilsland, L.G.; Dick, J.R.T.; Pryce, G.; Petrosino, S.; Di Marzo, V.; Baker, D.; Greensmith, L. Increasing cannabinoid levels by pharmacological and genetic manipulation delays disease progression in SOD1 mice. FASEB J., 2006, 20(7), 1003-1005.
[http://dx.doi.org/10.1096/fj.05-4743fje] [PMID: 16571781]

Kim, K.; Moore, D.H.; Makriyannis, A.; Abood, M.E. AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur. J. Pharmacol., 2006, 542(1-3), 100-105.
[http://dx.doi.org/10.1016/j.ejphar.2006.05.025] [PMID: 16781706]

Shoemaker, J.L.; Seely, K.A.; Reed, R.L.; Crow, J.P.; Prather, P.L. The CB2 cannabinoid agonist AM-1241 prolongs survival in a transgenic mouse model of amyotrophic lateral sclerosis when initiated at symptom onset. J. Neurochem., 2007, 101(1), 87-98.
[http://dx.doi.org/10.1111/j.1471-4159.2006.04346.x] [PMID: 17241118]

Yiangou, Y.; Facer, P.; Durrenberger, P.; Chessell, I.P.; Naylor, A.; Bountra, C.; Banati, R.R.; Anand, P. COX-2, CB2 and P2X7-immunoreactivities are increased in activated microglial cells/macrophages of multiple sclerosis and amyotrophic lateral sclerosis spinal cord. BMC Neurol., 2006, 6(1), 12.
[http://dx.doi.org/10.1186/1471-2377-6-12] [PMID: 16512913]

Fernández-Ruiz, J.; Romero, J.; Velasco, G.; Tolón, R.M.; Ramos, J.A.; Guzmán, M. Cannabinoid CB2 receptor: A new target for controlling neural cell survival? Trends Pharmacol. Sci., 2007, 28(1), 39-45.
[http://dx.doi.org/10.1016/j.tips.2006.11.001] [PMID: 17141334]

Ashton, J.; Glass, M. The cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol., 2007, 5(2), 73-80.
[http://dx.doi.org/10.2174/157015907780866884] [PMID: 18615177]

Witting, A.; Weydt, P.; Hong, S.; Kliot, M. Mőller, T.; Stella, N. Endocannabinoids accumulate in spinal cord of SOD1 G93A transgenic mice. J. Neurochem., 2004, 89(6), 1555-1557.
[http://dx.doi.org/10.1111/j.1471-4159.2004.02544.x] [PMID: 15189359]

Moreno-Martet, M.; Espejo-Porras, F. Fernández-Ruiz, J.; de Lago, E. Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex(®) -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis. CNS Neurosci. Ther., 2014, 20(9), 809-815.
[http://dx.doi.org/10.1111/cns.12262] [PMID: 24703394]

Sastre-Garriga, J.; Vila, C.; Clissold, S.; Montalban, X. THC and CBD oromucosal spray (Sativex ®) in the management of spasticity associated with multiple sclerosis. Expert Rev. Neurother., 2011, 11(5), 627-637.
[http://dx.doi.org/10.1586/ern.11.47] [PMID: 21456949]

Pertwee, R.G. Targeting the endocannabinoid system with cannabinoid receptor agonists: Pharmacological strategies and therapeutic possibilities. Philos. Trans. R. Soc. Lond. B Biol. Sci., 2012, 367(1607), 3353-3363.
[http://dx.doi.org/10.1098/rstb.2011.0381] [PMID: 23108552]

Roze, E.; Bonnet, C.; Betuing, S. Caboche, J. Huntington’s Disease. Adv. Exp. Med. Biol., 2010, 685, 45-63.
[http://dx.doi.org/10.1007/978-1-4419-6448-9_5] [PMID: 20687494]

Zuccato, C.; Valenza, M.; Cattaneo, E. Molecular mechanisms and potential therapeutical targets in Huntington’s disease. Physiol. Rev., 2010, 90(3), 905-981.
[http://dx.doi.org/10.1152/physrev.00041.2009] [PMID: 20664076]

Johnson, C.D.; Davidson, B.L. Huntington’s disease: Progress toward effective disease-modifying treatments and a cure. Hum. Mol. Genet., 2010, 19(R1), R98-R102.
[http://dx.doi.org/10.1093/hmg/ddq148] [PMID: 20421366]

Curtis, A.; Mitchell, I.; Patel, S.; Ives, N.; Rickards, H. A pilot study using nabilone for symptomatic treatment in Huntington’s disease. Mov. Disord., 2009, 24(15), 2254-2259.
[http://dx.doi.org/10.1002/mds.22809] [PMID: 19845035]

Curtis, A.; Rickards, H. Nabilone could treat chorea and irritability in Huntington’s disease. J. Neuropsychiatry Clin. Neurosci., 2006, 18(4), 553-554.
[http://dx.doi.org/10.1176/jnp.2006.18.4.553] [PMID: 17135385]

Müller-Vahl, K.R.; Schneider, U.; Emrich, H.M. Nabilone increases choreatic movements in Huntington’s disease. Mov. Disord., 1999, 14(6), 1038-1040.
[http://dx.doi.org/10.1002/1531-8257(199911)14:6<1038:AID-MDS1024>3.0.CO;2-7] [PMID: 10584686]

Consroe, P.; Laguna, J.; Allender, J.; Snider, S.; Stern, L.; Sandyk, R.; Kennedy, K.; Schram, K. Controlled clinical trial of cannabidiol in Huntington’s disease. Pharmacol. Biochem. Behav., 1991, 40(3), 701-708.
[http://dx.doi.org/10.1016/0091-3057(91)90386-G] [PMID: 1839644]

Sagredo, O.; Ramos, J.A.; Decio, A.; Mechoulam, R. Fernández-Ruiz, J. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV 1 and adenosine A 2A receptors. Eur. J. Neurosci., 2007, 26(4), 843-851.
[http://dx.doi.org/10.1111/j.1460-9568.2007.05717.x] [PMID: 17672854]

Valdeolivas, S.; Navarrete, C.; Cantarero, I.; Bellido, M.L. Muñoz, E.; Sagredo, O. Neuroprotective properties of cannabigerol in Huntington’s disease: Studies in R6/2 mice and 3-nitropropionate-lesioned mice. Neurotherapeutics, 2015, 12(1), 185-199.
[http://dx.doi.org/10.1007/s13311-014-0304-z] [PMID: 25252936]

Blázquez, C.; Chiarlone, A.; Sagredo, O.; Aguado, T.; Pazos, M.R.; Resel, E.; Palazuelos, J.; Julien, B.; Salazar, M.; Börner, C.; Benito, C.; Carrasco, C.; Diez-Zaera, M.; Paoletti, P.; Díaz-Hernández, M.; Ruiz, C.; Sendtner, M.; Lucas, J.J.; de Yébenes, J.G.; Marsicano, G.; Monory, K.; Lutz, B.; Romero, J.; Alberch, J.; Ginés, S.; Kraus, J.; Fernández-Ruiz, J.; Galve-Roperh, I.; Guzmán, M. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain, 2011, 134(1), 119-136.
[http://dx.doi.org/10.1093/brain/awq278] [PMID: 20929960]

Palazuelos, J.; Aguado, T.; Pazos, M.R.; Julien, B.; Carrasco, C.; Resel, E.; Sagredo, O.; Benito, C.; Romero, J.; Azcoitia, I. Fernández-Ruiz, J.; Guzmán, M.; Galve-Roperh, I. Microglial CB2 cannabinoid receptors are neuroprotective in Huntington’s disease excitotoxicity. Brain, 2009, 132(11), 3152-3164.
[http://dx.doi.org/10.1093/brain/awp239] [PMID: 19805493]

Sagredo, O. González, S.; Aroyo, I.; Pazos, M.R.; Benito, C.; Lastres-Becker, I.; Romero, J.P.; Tolón, R.M.; Mechoulam, R.; Brouillet, E.; Romero, J.; Fernández-Ruiz, J. Cannabinoid CB 2 receptor agonists protect the striatum against malonate toxicity: Relevance for Huntington’s disease. Glia, 2009, 57(11), 1154-1167.
[http://dx.doi.org/10.1002/glia.20838] [PMID: 19115380]

Pintor, A.; Tebano, M.T.; Martire, A.; Grieco, R.; Galluzzo, M.; Scattoni, M.L.; Pèzzola, A.; Coccurello, R.; Felici, F.; Cuomo, V.; Piomelli, D.; Calamandrei, G.; Popoli, P. The cannabinoid receptor agonist WIN 55,212-2 attenuates the effects induced by quinolinic acid in the rat striatum. Neuropharmacology, 2006, 51(5), 1004-1012.
[http://dx.doi.org/10.1016/j.neuropharm.2006.06.013] [PMID: 16895732]

Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P. Fernández-Ruiz, J.; Brouillet, E. Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo. Neuroreport, 2004, 15(15), 2375-2379.
[http://dx.doi.org/10.1097/00001756-200410250-00015] [PMID: 15640759]

Lastres-Becker, I.; Bizat, N.; Boyer, F.; Hantraye, P.; Brouillet, E. Fernández-Ruiz, J. Effects of cannabinoids in the rat model of Huntington’s disease generated by an intrastriatal injection of malonate. Neuroreport, 2003, 14(6), 813-816.
[http://dx.doi.org/10.1097/00001756-200305060-00007] [PMID: 12858038]

Sagredo, O.; Pazos, M.R.; Satta, V.; Ramos, J.A.; Pertwee, R.G. Fernández-Ruiz, J. Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington’s disease. J. Neurosci. Res., 2011, 89(9), 1509-1518.
[http://dx.doi.org/10.1002/jnr.22682] [PMID: 21674569]

Valdeolivas, S.; Satta, V.; Pertwee, R.G. Fernández-Ruiz, J.; Sagredo, O. Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington’s disease: Role of CB1 and CB2 receptors. ACS Chem. Neurosci., 2012, 3(5), 400-406.
[http://dx.doi.org/10.1021/cn200114w] [PMID: 22860209]

Valdeolivas, S.; Sagredo, O.; Delgado, M.; Pozo, M. Fernández-Ruiz, J. Effects of a sativex-like combination of phytocannabinoids on disease progression in R6/2 mice, an experimental model of huntington’s disease. Int. J. Mol. Sci., 2017, 18(4), 684.
[http://dx.doi.org/10.3390/ijms18040684] [PMID: 28333097]

Dowie, M.J.; Howard, M.L.; Nicholson, L.F.B.; Faull, R.L.M.; Hannan, A.J.; Glass, M. Behavioural and molecular consequences of chronic cannabinoid treatment in Huntington’s disease transgenic mice. Neuroscience, 2010, 170(1), 324-336.
[http://dx.doi.org/10.1016/j.neuroscience.2010.06.056] [PMID: 20600638]

Wade, D. Evaluation of the safety and tolerability profile of Sativex ®: is it reassuring enough? Expert Rev. Neurother., 2012, 12(S4), 9-14.
[http://dx.doi.org/10.1586/ern.12.12] [PMID: 22509986]

López-Sendón, M.J.L.; García, C.J.; Trigo, C.P.; Ruiz, R.C.; García, R.G.; Alonso, A.M.A.A.; García de Yébenes, M.J.; Tolón, R.M.; Galve-Roperh, I.; Sagredo, O.; Valdeolivas, S.; Resel, E.; Ortega-Gutierrez, S.; García-Bermejo, M.L.; Fernández, R.J.; Guzmán, M.; García de, Y.P.J. A double-blind, randomized, cross-over, placebo-controlled, pilot trial with Sativex in Huntington’s disease. J. Neurol., 2016, 263(7), 1390-1400.
[http://dx.doi.org/10.1007/s00415-016-8145-9] [PMID: 27159993]

Ferrante, R.J.; Andreassen, O.A.; Jenkins, B.G.; Dedeoglu, A.; Kuemmerle, S.; Kubilus, J.K.; Kaddurah-Daouk, R.; Hersch, S.M.; Beal, M.F. Neuroprotective effects of creatine in a transgenic mouse model of Huntington’s disease. J. Neurosci., 2000, 20(12), 4389-4397.
[http://dx.doi.org/10.1523/JNEUROSCI.20-12-04389.2000] [PMID: 10844007]

Andreassen, O.A.; Dedeoglu, A.; Ferrante, R.J.; Jenkins, B.G.; Ferrante, K.L.; Thomas, M.; Friedlich, A.; Browne, S.E.; Schilling, G.; Borchelt, D.R.; Hersch, S.M.; Ross, C.A.; Beal, M.F. Creatine increase survival and delays motor symptoms in a transgenic animal model of Huntington’s disease. Neurobiol. Dis., 2001, 8(3), 479-491.
[http://dx.doi.org/10.1006/nbdi.2001.0406] [PMID: 11447996]

Tabrizi, S.J.; Blamire, A.M.; Manners, D.N.; Rajagopalan, B.; Styles, P.; Schapira, A.H.V.; Warner, T.T. Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study. Neurology, 2003, 61(1), 141-142.
[http://dx.doi.org/10.1212/01.WNL.0000070186.97463.A7] [PMID: 12847181]

Louis, D.N.; Perry, A.; Reifenberger, G.; von Deimling, A.; Figarella-Branger, D.; Cavenee, W.K.; Ohgaki, H.; Wiestler, O.D.; Kleihues, P.; Ellison, D.W. The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol., 2016, 131(6), 803-820.
[http://dx.doi.org/10.1007/s00401-016-1545-1] [PMID: 27157931]

Nieder, C.; Adam, M.; Molls, M.; Grosu, A.L. Therapeutic options for recurrent high-grade glioma in adult patients: Recent advances. Crit. Rev. Oncol. Hematol., 2006, 60(3), 181-193.
[http://dx.doi.org/10.1016/j.critrevonc.2006.06.007] [PMID: 16875833]

Wong, M.L.H.; Kaye, A.H.; Hovens, C.M. Targeting malignant glioma survival signalling to improve clinical outcomes. J. Clin. Neurosci., 2007, 14(4), 301-308.
[http://dx.doi.org/10.1016/j.jocn.2006.11.005] [PMID: 17276069]

Ostrom, Q.T.; Bauchet, L.; Davis, F.G.; Deltour, I.; Fisher, J.L.; Langer, C.E.; Pekmezci, M.; Schwartzbaum, J.A.; Turner, M.C.; Walsh, K.M.; Wrensch, M.R.; Barnholtz-Sloan, J.S. The epidemiology of glioma in adults: A “state of the science” review. Neuro-oncol., 2014, 16(7), 896-913.
[http://dx.doi.org/10.1093/neuonc/nou087] [PMID: 24842956]

Reni, M.; Mazza, E.; Zanon, S.; Gatta, G.; Vecht, C.J. Central nervous system gliomas. Crit. Rev. Oncol. Hematol., 2017, 113, 213-234.
[http://dx.doi.org/10.1016/j.critrevonc.2017.03.021] [PMID: 28427510]

Louis, D.N.; Ohgaki, H.; Wiestler, O.D.; Cavenee, W.K.; Burger, P.C.; Jouvet, A.; Scheithauer, B.W.; Kleihues, P. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol., 2007, 114(2), 97-109.
[http://dx.doi.org/10.1007/s00401-007-0243-4] [PMID: 17618441]

Yang, L.J.; Zhou, C.F.U.; Lin, Z.X. Temozolomide and radiotherapy for newly diagnosed glioblastoma multiforme: A systematic review. Cancer Invest., 2014, 32(2), 31-36.
[http://dx.doi.org/10.3109/07357907.2013.861474] [PMID: 24328555]

Brandes, A.A.; Bartolotti, M.; Tosoni, A.; Franceschi, E. Nitrosoureas in the management of malignant gliomas. Curr. Neurol. Neurosci. Rep., 2016, 16(2), 13.
[http://dx.doi.org/10.1007/s11910-015-0611-8] [PMID: 26750128]

Brennan, C.W.; Verhaak, R.G.W.; McKenna, A.; Campos, B.; Noushmehr, H.; Salama, S.R.; Zheng, S.; Chakravarty, D.; Sanborn, J.Z.; Berman, S.H.; Beroukhim, R.; Bernard, B.; Wu, C.J.; Genovese, G.; Shmulevich, I.; Barnholtz-Sloan, J.; Zou, L.; Vegesna, R.; Shukla, S.A.; Ciriello, G.; Yung, W.K.; Zhang, W.; Sougnez, C.; Mikkelsen, T.; Aldape, K.; Bigner, D.D.; Van Meir, E.G.; Prados, M.; Sloan, A.; Black, K.L.; Eschbacher, J.; Finocchiaro, G.; Friedman, W.; Andrews, D.W.; Guha, A.; Iacocca, M.; O’Neill, B.P.; Foltz, G.; Myers, J.; Weisenberger, D.J.; Penny, R.; Kucherlapati, R.; Perou, C.M.; Hayes, D.N.; Gibbs, R.; Marra, M.; Mills, G.B.; Lander, E.; Spellman, P.; Wilson, R.; Sander, C.; Weinstein, J.; Meyerson, M.; Gabriel, S.; Laird, P.W.; Haussler, D.; Getz, G.; Chin, L.; Benz, C.; Barnholtz-Sloan, J.; Barrett, W.; Ostrom, Q.; Wolinsky, Y.; Black, K.L.; Bose, B.; Boulos, P.T.; Boulos, M.; Brown, J.; Czerinski, C.; Eppley, M.; Iacocca, M.; Kempista, T.; Kitko, T.; Koyfman, Y.; Rabeno, B.; Rastogi, P.; Sugarman, M.; Swanson, P.; Yalamanchii, K.; Otey, I.P.; Liu, Y.S.; Xiao, Y.; Auman, J.T.; Chen, P-C.; Hadjipanayis, A.; Lee, E.; Lee, S.; Park, P.J.; Seidman, J.; Yang, L.; Kucherlapati, R.; Kalkanis, S.; Mikkelsen, T.; Poisson, L.M.; Raghunathan, A.; Scarpace, L.; Bernard, B.; Bressler, R.; Eakin, A.; Iype, L.; Kreisberg, R.B.; Leinonen, K.; Reynolds, S.; Rovira, H.; Thorsson, V.; Shmulevich, I.; Annala, M.J.; Penny, R.; Paulauskis, J.; Curley, E.; Hatfield, M.; Mallery, D.; Morris, S.; Shelton, T.; Shelton, C.; Sherman, M.; Yena, P.; Cuppini, L.; DiMeco, F.; Eoli, M.; Finocchiaro, G.; Maderna, E.; Pollo, B.; Saini, M.; Balu, S.; Hoadley, K.A.; Li, L.; Miller, C.R.; Shi, Y.; Topal, M.D.; Wu, J.; Dunn, G.; Giannini, C.; O’Neill, B.P.; Aksoy, B.A.; Antipin, Y.; Borsu, L.; Berman, S.H.; Brennan, C.W.; Cerami, E.; Chakravarty, D.; Ciriello, G.; Gao, J.; Gross, B.; Jacobsen, A.; Ladanyi, M.; Lash, A.; Liang, Y.; Reva, B.; Sander, C.; Schultz, N.; Shen, R.; Socci, N.D.; Viale, A.; Ferguson, M.L.; Chen, Q-R.; Demchok, J.A.; Dillon, L.A.L.; Shaw, K.R.M.; Sheth, M.; Tarnuzzer, R.; Wang, Z.; Yang, L.; Davidsen, T.; Guyer, M.S.; Ozenberger, B.A.; Sofia, H.J.; Bergsten, J.; Eckman, J.; Harr, J.; Myers, J.; Smith, C.; Tucker, K.; Winemiller, C.; Zach, L.A.; Ljubimova, J.Y.; Eley, G.; Ayala, B.; Jensen, M.A.; Kahn, A.; Pihl, T.D.; Pot, D.A.; Wan, Y.; Eschbacher, J.; Foltz, G.; Hansen, N.; Hothi, P.; Lin, B.; Shah, N.; Yoon, J.; Lau, C.; Berens, M.; Ardlie, K.; Beroukhim, R.; Carter, S.L.; Cherniack, A.D.; Noble, M.; Cho, J.; Cibulskis, K.; DiCara, D.; Frazer, S.; Gabriel, S.B.; Gehlenborg, N.; Gentry, J.; Heiman, D.; Kim, J.; Jing, R.; Lander, E.S.; Lawrence, M.; Lin, P.; Mallard, W.; Meyerson, M.; Onofrio, R.C.; Saksena, G.; Schumacher, S.; Sougnez, C.; Stojanov, P.; Tabak, B.; Voet, D.; Zhang, H.; Zou, L.; Getz, G.; Dees, N.N.; Ding, L.; Fulton, L.L.; Fulton, R.S.; Kanchi, K-L.; Mardis, E.R.; Wilson, R.K.; Baylin, S.B.; Andrews, D.W.; Harshyne, L.; Cohen, M.L.; Devine, K.; Sloan, A.E.; VandenBerg, S.R.; Berger, M.S.; Prados, M.; Carlin, D.; Craft, B.; Ellrott, K.; Goldman, M.; Goldstein, T.; Grifford, M.; Haussler, D.; Ma, S.; Ng, S.; Salama, S.R.; Sanborn, J.Z.; Stuart, J.; Swatloski, T.; Waltman, P.; Zhu, J.; Foss, R.; Frentzen, B.; Friedman, W.; McTiernan, R.; Yachnis, A.; Hayes, D.N.; Perou, C.M.; Zheng, S.; Vegesna, R.; Mao, Y.; Akbani, R.; Aldape, K.; Bogler, O.; Fuller, G.N.; Liu, W.; Liu, Y.; Lu, Y.; Mills, G.; Protopopov, A.; Ren, X.; Sun, Y.; Wu, C-J.; Yung, W.K.A.; Zhang, W.; Zhang, J.; Chen, K.; Weinstein, J.N.; Chin, L.; Verhaak, R.G.W.; Noushmehr, H.; Weisenberger, D.J.; Bootwalla, M.S.; Lai, P.H.; Triche, T.J., Jr; Van Den Berg, D.J.; Laird, P.W.; Gutmann, D.H.; Lehman, N.L.; VanMeir, E.G.; Brat, D.; Olson, J.J.; Mastrogianakis, G.M.; Devi, N.S.; Zhang, Z.; Bigner, D.; Lipp, E.; McLendon, R. The somatic genomic landscape of glioblastoma. Cell, 2013, 155(2), 462-477.
[http://dx.doi.org/10.1016/j.cell.2013.09.034] [PMID: 24120142]

Verhaak, R.G.W.; Hoadley, K.A.; Purdom, E.; Wang, V.; Qi, Y.; Wilkerson, M.D.; Miller, C.R.; Ding, L.; Golub, T.; Mesirov, J.P.; Alexe, G.; Lawrence, M.; O’Kelly, M.; Tamayo, P.; Weir, B.A.; Gabriel, S.; Winckler, W.; Gupta, S.; Jakkula, L.; Feiler, H.S.; Hodgson, J.G.; James, C.D.; Sarkaria, J.N.; Brennan, C.; Kahn, A.; Spellman, P.T.; Wilson, R.K.; Speed, T.P.; Gray, J.W.; Meyerson, M.; Getz, G.; Perou, C.M.; Hayes, D.N. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010, 17(1), 98-110.
[http://dx.doi.org/10.1016/j.ccr.2009.12.020] [PMID: 20129251]

Anjum, K.; Shagufta, B.I.; Abbas, S.Q.; Patel, S.; Khan, I.; Shah, S.A.A.; Akhter, N.; Hassan, S.S. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomed. Pharmacother., 2017, 92, 681-689.
[http://dx.doi.org/10.1016/j.biopha.2017.05.125] [PMID: 28582760]

Szopa, W.; Burley, T.A.; Kramer-Marek, G.; Kaspera, W. Diagnostic and therapeutic biomarkers in glioblastoma: Current status and future perspectives. BioMed Res. Int., 2017, 2017, 1-13.
[http://dx.doi.org/10.1155/2017/8013575] [PMID: 28316990]

Velasco, G. Hernández-Tiedra, S.; Dávila, D.; Lorente, M. The use of cannabinoids as anticancer agents. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2016, 64, 259-266.
[http://dx.doi.org/10.1016/j.pnpbp.2015.05.010] [PMID: 26071989]

Velasco, G. Sánchez, C.; Guzmán, M. Towards the use of cannabinoids as antitumour agents. Nat. Rev. Cancer, 2012, 12(6), 436-444.
[http://dx.doi.org/10.1038/nrc3247] [PMID: 22555283]

Carracedo, A.; Lorente, M.; Egia, A. Blázquez, C.; García, S.; Giroux, V.; Malicet, C.; Villuendas, R.; Gironella, M.; González-Feria, L.; Piris, M.Á; Iovanna, J.L.; Guzmán, M.; Velasco, G. The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell, 2006, 9(4), 301-312.
[http://dx.doi.org/10.1016/j.ccr.2006.03.005] [PMID: 16616335]

Salazar, M.; Carracedo, A. Salanueva, Í.J.; Hernández-Tiedra, S.; Lorente, M.; Egia, A.; Vázquez, P.; Blázquez, C.; Torres, S.; García, S.; Nowak, J.; Fimia, G.M.; Piacentini, M.; Cecconi, F.; Pandolfi, P.P.; González-Feria, L.; Iovanna, J.L.; Guzmán, M.; Boya, P.; Velasco, G. Cannabinoid action induces autophagy-mediated cell death through stimulation of ER stress in human glioma cells. J. Clin. Invest., 2009, 119(5), 1359-1372.
[http://dx.doi.org/10.1172/JCI37948] [PMID: 19425170]

Guzmán M.; Duarte, M.J.; Blázquez, C.; Ravina, J.; Rosa, M.C.; Galve-Roperh, I.; Sánchez, C.; Velasco, G.; González-Feria, L. A pilot clinical study of Δ9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br. J. Cancer, 2006, 95(2), 197-203.
[http://dx.doi.org/10.1038/sj.bjc.6603236] [PMID: 16804518]

Izzo, A.A.; Borrelli, F.; Capasso, R.; Di Marzo, V.; Mechoulam, R. Non-psychotropic plant cannabinoids: New therapeutic opportunities from an ancient herb. Trends Pharmacol. Sci., 2009, 30(10), 515-527.
[http://dx.doi.org/10.1016/j.tips.2009.07.006] [PMID: 19729208]

Massi, P.; Vaccani, A.; Bianchessi, S.; Costa, B.; Macchi, P.; Parolaro, D. The non-psychoactive cannabidiol triggers caspase activation and oxidative stress in human glioma cells. Cell. Mol. Life Sci., 2006, 63(17), 2057-2066.
[http://dx.doi.org/10.1007/s00018-006-6156-x] [PMID: 16909207]

Massi, P.; Vaccani, A.; Ceruti, S.; Colombo, A.; Abbracchio, M.P.; Parolaro, D. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines. J. Pharmacol. Exp. Ther., 2004, 308(3), 838-845.
[http://dx.doi.org/10.1124/jpet.103.061002] [PMID: 14617682]

Massi, P.; Valenti, M.; Vaccani, A.; Gasperi, V.; Perletti, G.; Marras, E.; Fezza, F.; Maccarrone, M.; Parolaro, D. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J. Neurochem., 2008, 104(4), 1091-1100.
[http://dx.doi.org/10.1111/j.1471-4159.2007.05073.x] [PMID: 18028339]

McAllister, S.D.; Christian, R.T.; Horowitz, M.P.; Garcia, A.; Desprez, P.Y. Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells. Mol. Cancer Ther., 2007, 6(11), 2921-2927.
[http://dx.doi.org/10.1158/1535-7163.MCT-07-0371] [PMID: 18025276]

Ligresti, A.; Moriello, A.S.; Starowicz, K.; Matias, I.; Pisanti, S.; De Petrocellis, L.; Laezza, C.; Portella, G.; Bifulco, M.; Di Marzo, V. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast carcinoma. J. Pharmacol. Exp. Ther., 2006, 318(3), 1375-1387.
[http://dx.doi.org/10.1124/jpet.106.105247] [PMID: 16728591]

Marcu, J.P.; Christian, R.T.; Lau, D.; Zielinski, A.J.; Horowitz, M.P.; Lee, J.; Pakdel, A.; Allison, J.; Limbad, C.; Moore, D.H.; Yount, G.L.; Desprez, P.Y.; McAllister, S.D. Cannabidiol enhances the inhibitory effects of delta9-tetrahydrocannabinol on human glioblastoma cell proliferation and survival. Mol. Cancer Ther., 2010, 9(1), 180-189.
[http://dx.doi.org/10.1158/1535-7163.MCT-09-0407] [PMID: 20053780]

Scott, K.A.; Dalgleish, A.G.; Liu, W.M. The combination of cannabidiol and Δ9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Mol. Cancer Ther., 2014, 13(12), 2955-2967.
[http://dx.doi.org/10.1158/1535-7163.MCT-14-0402] [PMID: 25398831]

Torres, S.; Lorente, M. Rodríguez-Fornés, F.; Hernández-Tiedra, S.; Salazar, M.; García-Taboada, E.; Barcia, J.; Guzmán, M.; Velasco, G. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol. Cancer Ther., 2011, 10(1), 90-103.
[http://dx.doi.org/10.1158/1535-7163.MCT-10-0688] [PMID: 21220494]

López-Valero, I.; Torres, S.; Salazar-Roa, M.; García-Taboada, E.; Hernández-Tiedra, S.; Guzmán, M.; Sepúlveda, J.M.; Velasco, G.; Lorente, M. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochem. Pharmacol., 2018, 157, 275-284.
[http://dx.doi.org/10.1016/j.bcp.2018.08.023] [PMID: 30125556]

López-Valero, I.; Saiz-Ladera, C.; Torres, S.; Hernández-Tiedra, S.; García-Taboada, E.; Rodríguez-Fornés, F.; Barba, M.; Dávila, D.; Salvador-Tormo, N.; Guzmán, M.; Sepúlveda, J.M.; Sánchez-Gómez, P.; Lorente, M.; Velasco, G. Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide. Biochem. Pharmacol., 2018, 157, 266-274.
[http://dx.doi.org/10.1016/j.bcp.2018.09.007] [PMID: 30195736]

Nair, A.; Jacob, S. A simple practice guide for dose conversion between animals and human. J. Basic Clin. Pharm., 2016, 7(2), 27-31.
[http://dx.doi.org/10.4103/0976-0105.177703] [PMID: 27057123]

Deng, L.; Ng, L.; Ozawa, T.; Stella, N. Quantitative analyses of synergistic responses between cannabidiol and DNA-damaging agents on the proliferation and viability of glioblastoma and neural progenitor cells in culture. J. Pharmacol. Exp. Ther., 2017, 360(1), 215-224.
[http://dx.doi.org/10.1124/jpet.116.236968] [PMID: 27821713]

Würstle, S.; Schneider, F.; Ringel, F.; Gempt, J. Lämmer, F.; Delbridge, C.; Wu, W.; Schlegel, J. Temozolomide induces autophagy in primary and established glioblastoma cells in an EGFR independent manner. Oncol. Lett., 2017, 14(1), 322-328.
[http://dx.doi.org/10.3892/ol.2017.6107] [PMID: 28693171]

Patti, F. Cognitive impairment in multiple sclerosis. Mult. Scler., 2009, 15(1), 2-8.
[http://dx.doi.org/10.1177/1352458508096684] [PMID: 18805842]

Lynch, S.G.; Parmenter, B.A.; Denney, D.R. The association between cognitive impairment and physical disability in multiple sclerosis. Mult. Scler., 2005, 11(4), 469-476.
[http://dx.doi.org/10.1191/1352458505ms1182oa] [PMID: 16042232]

Rogers, J.M.; Panegyres, P.K. Cognitive impairment in multiple sclerosis: Evidence-based analysis and recommendations. J. Clin. Neurosci., 2007, 14(10), 919-927.
[http://dx.doi.org/10.1016/j.jocn.2007.02.006] [PMID: 17659875]

McDonald, J.; Schleifer, L.; Richards, J.B.; de Wit, H. Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology, 2003, 28(7), 1356-1365.
[http://dx.doi.org/10.1038/sj.npp.1300176] [PMID: 12784123]

D’Souza, D.C.; Abi-Saab, W.M.; Madonick, S.; Forselius-Bielen, K.; Doersch, A.; Braley, G.; Gueorguieva, R.; Cooper, T.B.; Krystal, J.H. Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction. Biol. Psychiatry, 2005, 57(6), 594-608.
[http://dx.doi.org/10.1016/j.biopsych.2004.12.006] [PMID: 15780846]

Moore, C.; Rana, S.; Coulter, C.; Day, D.; Vincent, M.; Soares, J. Detection of conjugated 11-nor-Delta9-tetrahydrocannabinol-9-carboxylic acid in oral fluid. J. Anal. Toxicol., 2007, 31(4), 187-194.
[http://dx.doi.org/10.1093/jat/31.4.187] [PMID: 17555641]

Russo, M.; De Luca, R.; Torrisi, M.; Rifici, C.; Sessa, E.; Bramanti, P.; Naro, A. Calabrò, R.S. Should we care about sativex-induced neurobehavioral effects? A 6-month follow-up study. Eur. Rev. Med. Pharmacol. Sci., 2016, 20(14), 3127-3133.
[PMID: 27460745]

Rekand, T. THC:CBD spray and MS spasticity symptoms: Data from latest studies. Eur. Neurol., 2014, 71(Suppl. 1), 4-9.
[http://dx.doi.org/10.1159/000357742] [PMID: 24457846]

Aragona, M.; Onesti, E.; Tomassini, V.; Conte, A.; Gupta, S.; Gilio, F.; Pantano, P.; Pozzilli, C.; Inghilleri, M. Psychopathological and cognitive effects of therapeutic cannabinoids in multiple sclerosis: A double-blind, placebo controlled, crossover study. Clin. Neuropharmacol., 2009, 32(1), 41-47.
[http://dx.doi.org/10.1097/WNF.0b013e3181633497] [PMID: 18978501]

Russo, M.; Rifici, C.; Sessa, E.; D’Aleo, G.; Bramanti, P. Calabrò, R.S. Sativex-induced neurobehavioral effects: Causal or concausal? A practical advice! Daru, 2015, 23(1), 25.
[http://dx.doi.org/10.1186/s40199-015-0109-6] [PMID: 25881038]

Fava, M.; Kendler, K.S. Major depressive disorder. Neuron, 2000, 28(2), 335-341.
[http://dx.doi.org/10.1016/S0896-6273(00)00112-4] [PMID: 11144343]

Mechoulam, R.; Parker, L.A.; Gallily, R. Cannabidiol: An overview of some pharmacological aspects. J. Clin. Pharmacol., 2002, 42(S1), 11S-19S.
[http://dx.doi.org/10.1002/j.1552-4604.2002.tb05998.x] [PMID: 12412831]

Ilan, A.B.; Gevins, A.; Coleman, M.; ElSohly, M.A.; de Wit, H. Neurophysiological and subjective profile of marijuana with varying concentrations of cannabinoids. Behav. Pharmacol., 2005, 16(5-6), 487-496.
[http://dx.doi.org/10.1097/00008877-200509000-00023] [PMID: 16148455]

Fadda, P.; Robinson, L.; Fratta, W.; Pertwee, R.G.; Riedel, G. Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats. Neuropharmacology, 2004, 47(8), 1170-1179.
[http://dx.doi.org/10.1016/j.neuropharm.2004.08.009] [PMID: 15567426]

Hall, W.; Degenhardt, L. Adverse health effects of non-medical cannabis use. Lancet, 2009, 374(9698), 1383-1391.
[http://dx.doi.org/10.1016/S0140-6736(09)61037-0] [PMID: 19837255]

Organization, W.H. Health and Social Effects of Nonmedical Cannabis Use (The); World Health Organization, 2016.

Marlatt, G.A. Cannabis dependence: its nature, consequences and treatment; Cambridge university press, 2006.

Gates, P.J.; Sabioni, P.; Copeland, J.; Le Foll, B.; Gowing, L. Psychosocial interventions for cannabis use disorder. Cochrane Database Syst. Rev., 2016, 2016(5), CD005336.
[PMID: 27149547]

Johnston, J. A double blind, randomised, placebo controlled trial of lithium carbonate for the management of cannabis withdrawal: Paper 220. Drug Alcohol Rev., 2013, 32.

Danovitch, I.; Gorelick, D.A. State of the art treatments for cannabis dependence. Psychiatr. Clin. North Am., 2012, 35(2), 309-326.
[http://dx.doi.org/10.1016/j.psc.2012.03.003] [PMID: 22640758]

Vandrey, R.; Haney, M. Pharmacotherapy for cannabis dependence: how close are we? CNS Drugs, 2009, 23(7), 543-553.
[http://dx.doi.org/10.2165/00023210-200923070-00001] [PMID: 19552483]

Copeland, J.; Clement, N.; Swift, W. Cannabis use, harms and the management of cannabis use disorder. Neuropsychiatry, 2014, 4(1), 55-63.
[http://dx.doi.org/10.2217/npy.13.90]

Carpenter, K.M.; McDowell, D.; Brooks, D.J.; Cheng, W.Y.; Levin, F.R. A preliminary trial: Double-blind comparison of nefazodone, bupropion-SR, and placebo in the treatment of cannabis dependence. Am. J. Addict., 2009, 18(1), 53-64.
[http://dx.doi.org/10.1080/10550490802408936] [PMID: 19219666]

Haney, M.; Hart, C.L.; Vosburg, S.K.; Nasser, J.; Bennett, A.; Zubaran, C.; Foltin, R.W. Marijuana withdrawal in humans: Effects of oral THC or divalproex. Neuropsychopharmacology, 2004, 29(1), 158-170.
[http://dx.doi.org/10.1038/sj.npp.1300310] [PMID: 14560320]

Haney, M.; Hart, C.L.; Vosburg, S.K.; Comer, S.D.; Reed, S.C.; Foltin, R.W. Effects of THC and lofexidine in a human laboratory model of marijuana withdrawal and relapse. Psychopharmacology, 2008, 197(1), 157-168.
[http://dx.doi.org/10.1007/s00213-007-1020-8] [PMID: 18161012]

Gray, K.M.; Carpenter, M.J.; Baker, N.L.; DeSantis, S.M.; Kryway, E.; Hartwell, K.J.; McRae-Clark, A.L.; Brady, K.T. A double-blind randomized controlled trial of N-acetylcysteine in cannabis-dependent adolescents. Am. J. Psychiatry, 2012, 169(8), 805-812.
[http://dx.doi.org/10.1176/appi.ajp.2012.12010055] [PMID: 22706327]

Darke, S.; Farrell, M. Would legalizing illicit opioids reduce overdose fatalities? Implications from a natural experiment. Addiction, 2014, 109(8), 1237-1242.
[http://dx.doi.org/10.1111/add.12456] [PMID: 24456133]

Budney, A.J.; Radonovich, K.J.; Higgins, S.T.; Wong, C.J. Adults seeking treatment for marijuana dependence: A comparison with cocaine-dependent treatment seekers. Exp. Clin. Psychopharmacol., 1998, 6(4), 419-426.
[http://dx.doi.org/10.1037/1064-1297.6.4.419] [PMID: 9861556]

Bhardwaj, A.K.; Allsop, D.J.; Copeland, J.; McGregor, I.S.; Dunlop, A.; Shanahan, M.; Bruno, R.; Phung, N.; Montebello, M.; Sadler, C.; Gugusheff, J.; Jackson, M.; Luksza, J.; Lintzeris, N. Randomised Controlled Trial (RCT) of cannabinoid replacement therapy (Nabiximols) for the management of treatment-resistant cannabis dependent patients: A study protocol. BMC Psychiatry, 2018, 18(1), 140.
[http://dx.doi.org/10.1186/s12888-018-1682-2] [PMID: 29776349]

Karschner, E.L.; Darwin, W.D.; Goodwin, R.S.; Wright, S.; Huestis, M.A. Plasma cannabinoid pharmacokinetics following controlled oral delta9-tetrahydrocannabinol and oromucosal cannabis extract administration. Clin. Chem., 2011, 57(1), 66-75.
[http://dx.doi.org/10.1373/clinchem.2010.152439] [PMID: 21078841]

Trigo, J.M.; Soliman, A.; Staios, G.; Quilty, L.; Fischer, B.; George, T.P.; Rehm, J.; Selby, P.; Barnes, A.J.; Huestis, M.A.; Le Foll, B. Sativex associated with behavioral-relapse prevention strategy as treatment for cannabis dependence. J. Addict. Med., 2016, 10(4), 274-279.
[http://dx.doi.org/10.1097/ADM.0000000000000229] [PMID: 27261670]

Trigo, J.M.; Lagzdins, D.; Rehm, J.; Selby, P.; Gamaleddin, I.; Fischer, B.; Barnes, A.J.; Huestis, M.A.; Le Foll, B. Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings. Drug Alcohol Depend., 2016, 161, 298-306.
[http://dx.doi.org/10.1016/j.drugalcdep.2016.02.020] [PMID: 26925704]

Mantovani, L.G.; Cozzolino, P.; Cortesi, P.A.; Patti, F. Cost-effectiveness analysis of cannabinoid oromucosal spray use for the management of spasticity in subjects with multiple sclerosis. Clin. Drug Investig., 2020, 40(4), 319-326.
[http://dx.doi.org/10.1007/s40261-020-00895-6] [PMID: 32130684]

Freidel, M.; Tiel-Wilck, K.; Schreiber, H.; Prechtl, A.; Essner, U.; Lang, M. Drug-resistant MS spasticity treatment with Sativex ® add-on and driving ability. Acta Neurol. Scand., 2015, 131(1), 9-16.
[http://dx.doi.org/10.1111/ane.12287] [PMID: 25208898]

Grao-Castellote, C.; Torralba-Collados, F.; Gonzalez, L.M.; Giner-Pascual, M. [Delta-9-tetrahydrocannabinol-cannabidiol in the treatment of spasticity in chronic spinal cord injury: A clinical experience]. Rev. Neurol., 2017, 65(7), 295-302.
[PMID: 28929471]

Vermersch, P.; Trojano, M. Tetrahydrocannabinol: Cannabidiol oromucosal spray for multiple sclerosis-related resistant spasticity in daily practice. Eur. Neurol., 2016, 76(5-6), 216-226.
[http://dx.doi.org/10.1159/000449413] [PMID: 27732980]

Serpell, M.G.; Notcutt, W.; Collin, C. Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis. J. Neurol., 2013, 260(1), 285-295.
[http://dx.doi.org/10.1007/s00415-012-6634-z] [PMID: 22878432]

Maniscalco, G.T.; Aponte, R.; Bruzzese, D.; Guarcello, G.; Manzo, V.; Napolitano, M.; Moreggia, O.; Chiariello, F.; Florio, C. THC/CBD oromucosal spray in patients with multiple sclerosis overactive bladder: A pilot prospective study. Neurol. Sci., 2018, 39(1), 97-102.
[http://dx.doi.org/10.1007/s10072-017-3148-6] [PMID: 29052091]

Patti, F.; Chisari, C.G.; Solaro, C.; Benedetti, M.D.; Berra, E.; Bianco, A.; Bruno Bossio, R.; Buttari, F.; Castelli, L.; Cavalla, P.; Cerqua, R.; Costantino, G.; Gasperini, C.; Guareschi, A.; Ippolito, D.; Lanzillo, R.; Maniscalco, G.T.; Matta, M.; Paolicelli, D.; Petrucci, L.; Pontecorvo, S.; Righini, I.; Russo, M.; Saccà, F.; Salamone, G.; Signoriello, E.; Spinicci, G.; Spitaleri, D.; Tavazzi, E.; Trotta, M.; Zaffaroni, M.; Zappia, M. Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: Results from a retrospective multicenter study. Neurol. Sci., 2020, 41(10), 2905-2913.
[http://dx.doi.org/10.1007/s10072-020-04413-6] [PMID: 32335779]

Meuth, S.G.; Henze, T.; Essner, U.; Trompke, C. Vila Silván, C. Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. Int. J. Neurosci., 2020, 130(12), 1199-1205.
[http://dx.doi.org/10.1080/00207454.2020.1730832] [PMID: 32065006]

Coghe, G.; Pau, M.; Corona, F.; Frau, J.; Lorefice, L.; Fenu, G.; Spinicci, G.; Mamusa, E.; Musu, L.; Massole, S.; Massa, R.; Marrosu, M.G.; Cocco, E. Walking improvements with nabiximols in patients with multiple sclerosis. J. Neurol., 2015, 262(11), 2472-2477.
[http://dx.doi.org/10.1007/s00415-015-7866-5] [PMID: 26239223]

Patti, F.; Messina, S.; Solaro, C.; Amato, M.P.; Bergamaschi, R.; Bonavita, S.; Bruno Bossio, R.; Brescia Morra, V.; Costantino, G.F.; Cavalla, P.; Centonze, D.; Comi, G.; Cottone, S.; Danni, M.; Francia, A.; Gajofatto, A.; Gasperini, C.; Ghezzi, A.; Iudice, A.; Lus, G.; Maniscalco, G.T.; Marrosu, M.G.; Matta, M.; Mirabella, M.; Montanari, E.; Pozzilli, C.; Rovaris, M.; Sessa, E.; Spitaleri, D.; Trojano, M.; Valentino, P.; Zappia, M. Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity. J. Neurol. Neurosurg. Psychiatry, 2016, 87(9), 944-951.
[http://dx.doi.org/10.1136/jnnp-2015-312591] [PMID: 27160523]

Russo, M. Calabrò, R.S.; Naro, A.; Sessa, E.; Rifici, C.; D’Aleo, G.; Leo, A.; De Luca, R.; Quartarone, A.; Bramanti, P. Sativex in the management of multiple sclerosis-related spasticity: role of the corticospinal modulation. Neural Plast., 2015, 2015, 1-6.
[http://dx.doi.org/10.1155/2015/656582] [PMID: 25699191]

Cooper, R.E.; Williams, E.; Seegobin, S.; Tye, C.; Kuntsi, J.; Asherson, P. Cannabinoids in attention-deficit/hyperactivity disorder: A randomised-controlled trial. Eur. Neuropsychopharmacol., 2017, 27(8), 795-808.
[http://dx.doi.org/10.1016/j.euroneuro.2017.05.005] [PMID: 28576350]

Wade, D.T.; Makela, P.; Robson, P.; House, H.; Bateman, C. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult. Scler., 2004, 10(4), 434-441.
[http://dx.doi.org/10.1191/1352458504ms1082oa] [PMID: 15327042]

Rog, D.; Nurmikko, T.; Young, C. Oromucosal Δ9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial. Clin. Ther., 2007, 29(9), 2068-2079.
[http://dx.doi.org/10.1016/j.clinthera.2007.09.013] [PMID: 18035205]

Trojano, M.; Vila, C. Effectiveness and tolerability of THC/CBD oromucosal spray for multiple sclerosis spasticity in Italy: First data from a large observational study. Eur. Neurol., 2015, 74(3-4), 178-185.
[http://dx.doi.org/10.1159/000441619] [PMID: 26571097]

Wade, D.T.; Makela, P.M.; House, H.; Bateman, C.; Robson, P. Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis. Mult. Scler., 2006, 12(5), 639-645.
[http://dx.doi.org/10.1177/1352458505070618] [PMID: 17086911]

Collin, C.; Davies, P.; Mutiboko, I.K.; Ratcliffe, S. Randomized controlled trial of cannabis-based medicine in spasticity caused by multiple sclerosis. Eur. J. Neurol., 2007, 14(3), 290-296.
[http://dx.doi.org/10.1111/j.1468-1331.2006.01639.x] [PMID: 17355549]

Haupts, M.; Vila, C.; Jonas, A.; Witte, K. Álvarez-Ossorio, L. Influence of previous failed antispasticity therapy on the efficacy and tolerability of THC:CBD oromucosal spray for multiple sclerosis spasticity. Eur. Neurol., 2016, 75(5-6), 236-243.
[http://dx.doi.org/10.1159/000445943] [PMID: 27160412]

Collin, C.; Ehler, E.; Waberzinek, G.; Alsindi, Z.; Davies, P.; Powell, K.; Notcutt, W.; O’Leary, C.; Ratcliffe, S. Nováková, I.; Zapletalova, O.; Piková, J.; Ambler, Z. A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis. Neurol. Res., 2010, 32(5), 451-459.
[http://dx.doi.org/10.1179/016164109X12590518685660] [PMID: 20307378]

Kavia, R.B.C.; De Ridder, D.; Constantinescu, C.S.; Stott, C.G.; Fowler, C.J. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult. Scler., 2010, 16(11), 1349-1359.
[http://dx.doi.org/10.1177/1352458510378020] [PMID: 20829244]

Notcutt, W.; Langford, R.; Davies, P.; Ratcliffe, S.; Potts, R. A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols). Mult. Scler., 2012, 18(2), 219-228.
[http://dx.doi.org/10.1177/1352458511419700] [PMID: 21878454]

Alessandria, G.; Meli, R.; Infante, M.T.; Vestito, L.; Capello, E.; Bandini, F. Long-term assessment of the cognitive effects of nabiximols in patients with multiple sclerosis: A pilot study. Clin. Neurol. Neurosurg., 2020, 196, 105990.
[http://dx.doi.org/10.1016/j.clineuro.2020.105990] [PMID: 32526487]

Squintani, G.; Donato, F.; Turri, M.; Deotto, L.; Teatini, F.; Moretto, G.; Erro, R. Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray. J. Neurol. Sci., 2016, 370, 263-268.
[http://dx.doi.org/10.1016/j.jns.2016.09.054] [PMID: 27772772]

Nurmikko, T.J.; Serpell, M.G.; Hoggart, B.; Toomey, P.J.; Morlion, B.J.; Haines, D. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain, 2007, 133(1), 210-220.
[http://dx.doi.org/10.1016/j.pain.2007.08.028] [PMID: 17997224]

Feliú, A.; Moreno-Martet, M.; Mecha, M.; Carrillo-Salinas, F.J.; de Lago, E.; Fernández-Ruiz, J.; Guaza, C. A S ativex ® -like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br. J. Pharmacol., 2015, 172(14), 3579-3595.
[http://dx.doi.org/10.1111/bph.13159] [PMID: 25857324]